Protalix BioTherapeutics to Present at the Canaccord Genuity 32nd Annual Growth Conference
August 09 2012 - 7:30AM
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX) announced
today that Yossi Maimon, the Company's Chief Financial Officer,
will present at the Canaccord Genuity 32nd Annual Growth Conference
on Thursday, August 16, 2012 at 8:30 AM ET at the InterContinental
Hotel in Boston, MA. A live webcast of the presentation will be
available at www.protalix.com on the event calendar page. A
replay will be archived and available after the conclusion of the
presentation for 30 days.
About Protalix
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell based
expression system, ProCellEx(R). Protalix's unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale
manner. Protalix's first approved product manufactured by
ProCellEx, ELELYSO™ (taliglucerase alfa), was approved for
marketing by the U.S. Food and Drug Administration on May 1, 2012
and is partnered with Pfizer for worldwide development and
commercialization, excluding Israel, where Protalix retains full
rights. Marketing applications for taliglucerase alfa have
been filed in Europe, Israel, Brazil and Australia. Protalix's
development pipeline also includes the following product
candidates: PRX-102, a modified version of the recombinant human
alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a
pegylated recombinant human acetylcholinesterase in development for
several therapeutic and prophylactic indications, a biodefense
program and an organophosphate-based pesticide treatment program;
an orally-delivered glucocerebrosidase enzyme that is naturally
encased in carrot cells, also for the treatment of Gaucher disease;
pr-antiTNF, a similar plant cell version of etanercept (Enbrel(R))
for the treatment of certain immune diseases such as rheumatoid
arthritis, juvenile idiopathic arthritis, ankylosing spondylitis,
psoriatic arthritis and plaque psoriasis; and others.
Forward Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. The terms
"anticipate," "believe," "estimate," "expect," "plan" and "intend"
and other words or phrases of similar import are intended to
identify forward-looking statements. These forward-looking
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. The statements in this
release are valid only as of the date hereof and we disclaim any
obligation to update this information.
CONTACT: Investor Contact
Tricia Swanson
The Trout Group, LLC
646-378-2953
tswanson@troutgroup.com
Media Contact
Jennifer Conrad or Kari Watson
MacDougall Biomedical Communications
781-235-3060
jconrad@macbiocom.com
kwatson@macbiocom.com